anisomycin and Carcinoma--Ehrlich-Tumor

Anisomycin eminently inhibits cell proliferation in vitro. The aim of this study was to explore the potential of anisomycin to treat tumors in vivo and its mechanism(s) of action. The results showed that peritumoral administration of anisomycin significantly suppressed Ehrlich ascites carcinoma (EAC) growth resulting in the survival of approximately 60% of the mice 90 days after EAC inoculation. Enhancement of infiltrating lymphocytes was noted in the tumor tissue, which was dramatically superior to adriamycin. The growth inhibitory rate of EAC cells was enhanced with increasing concentrations of anisomycin, following an enhanced apoptotic rate. The total apoptotic rate induced by 160 ng/ml of anisomycin was higher when compared to that induced by 500 ng/ml of adriamycin. DNA breakage and nanostructure changes were also noted in the EAC cells. The levels of caspase-3 mRNA, caspase-3 and cleaved-caspase-3 proteins in the anisomycin‑treated EAC cells were augmented in a dose- and time-dependent manner, following the activation of caspase-8 and caspase-9, which finally triggered PARP cleavage. The cleaved-caspase-3, cleaved-caspase-8 and cleaved-caspase-9 proteins were mainly localized in the nuclei of the cells. These results indicate that anisomycin efficaciously represses in vitro and in vivo growth of EAC cells through caspase signaling, significantly superior to the effects of adriamycin. This suggests the potential of anisomycin for the treatment of breast cancer.

Topics: Animals; Anisomycin; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Ehrlich Tumor; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Doxorubicin; Drug Screening Assays, Antitumor; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Tumor Burden

Thallium acetate (TIOAc) effectively stimulates poly(U)-directed Phe-tRNA binding to mouse ascitic tumour ribosomes under conditions when other ribosomal functions are completely blocked. The TI+ optimum is about 200 mM. The reaction is stimulated by EF-1, but not significantly by GTP. EF-1-dependent ribosomal GTPase is inhibited by T1+. The isolated Phe-tRNA . ribosome complex is relatively stable. The bound Phe-tRNA does not react with puromycin in the presence of 175 mM KCl. The complex formed in the presence of 90-100 mM TlOAc can, after isolation, be directly utilized for polyphenylalanine synthesis. The complex formed at 200 mM TlOAc is less active, apparently because of damage to the 60-S subunits. TlOAc at low concentrations (8 mM) stimulates K+ -containing poly(U)-translating systems, probably by stabilizing the translation complex.

Topics: Animals; Anisomycin; Binding Sites; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; GTP Phosphohydrolase-Linked Elongation Factors; Mice; Peptide Biosynthesis; Peptide Elongation Factors; Phenylalanine; Poly U; Protein Biosynthesis; Rats; Ribosomes; RNA, Transfer; RNA, Transfer, Amino Acyl; Thallium

Treatment of Ehrlich ascites cells with anisomycin induces an almost threefold increase in the level of native 60S ribosomal subunits. This increase is not the result of an increase in rate of synthesis or transport of these subunits but is caused by a defect in the joining of the 60S subunits to the smaller initiation complex to form an 80S complex. Experimental evidence for such a blocking of the "joining reaction" could be found in the formation of "half-mer"-type oligosomes and by the release of extra 40S subunits when these oligosomes were treated with ribonuclease. Cycloheximide, an inhibitor of the translocation reaction, and inhibitors of the initiation prevent the increase of native 60S subunits induced by anisomycin. Our results imply that the increse of 60S subunits induced by anisomycin may be helpful in estimating the amount of initiating mRNAs in the cell.

Topics: Animals; Anisomycin; Carcinoma, Ehrlich Tumor; Cell Fractionation; Cell Membrane; Cell Nucleus; Cells, Cultured; Centrifugation, Density Gradient; Neoplasm Proteins; Peptide Chain Initiation, Translational; Peptide Initiation Factors; Protein Binding; Pyrrolidines; Ribonucleases; Ribosomes